Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

January 15, 2015 updated by: University of Michigan Rogel Cancer Center

Phase II Evaluation of PTK787, an Oral Vascular Endothelial Growth Factor Inhibitor, in Patients With Non-Metastatic Androgen Independent Prostate Cancer

The purpose of this study is to evaluate PTK787/ZK 222584, a drug that blocks new blood vessel growth, in the treatment of patients with non-metastatic androgen independent prostate cancer. This study will assess the safety and tolerability of PTK787/ZK 222584, and evaluate serum vascular endothelial growth factor (VEGF) levels.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is an open-label, phase II trial of PTK787/ZK 222584. Patients will receive 750 mg daily for one week, 1000 mg daily for the second week, and then 1250 mg per day thereafter.

Response Assessment: In the absence of toxicity or clinical progression, patients will remain in the study until their PSA (Prostate-specific Antigen) has doubled from pretreatment baseline.

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Phase 2

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Histologic or cytologic diagnosis of prostate cancer
  • No evidence of metastatic disease
  • PSA-only progression despite androgen depravation therapy and antiandrogen withdrawal
  • Patients must maintain castrate levels of testosterone (<50ng/mL) or continue on LHRH ( Luteinizing Hormone-releasing Hormone) analog therapy.
  • ECOG (Eastern Cooperative Oncology Group) performance status of 0-2 (A measure of quality of life where 0 represents asymptomatic and 5 represents death)
  • No prior anti-VEGF therapy is allowed
  • No investigational or commercial agents or therapies other than LHRH agonists/antagonists may be administered concurrently with intent to treat the patient's malignancy
  • Age greater than or equal to 18 years
  • Life expectancy greater than 6 months
  • Normal organ and marrow function obtained within 14 days prior to registration
  • Must use adequate contraception prior to study entry and for the duration of study participation.

Exclusion Criteria:

  • Patients may continue on a daily multivitamin, but all other herbal or alternative food supplements must be discontinued before registration.
  • Patients must be on stable doses of bisphosphonates which have been started no less than 6 weeks prior to protocol therapy.
  • Uncontrolled incurrent illness
  • Patients with a "currently active" second malignancy are not eligible.
  • Major surgery less than or equal to 4 weeks prior to randomization
  • Prior chemotherapy less than or equal to 3 weeks prior to registration
  • Prior biologic or immunotherapy less than or equal to 2 weeks prior to registration
  • Prior investigational drugs of any kind less than or equal to 4 weeks prior to registration
  • Patients who have had full field radiotherapy less than or equal to 4 weeks or limited field radiotherapy equal or less than 2 weeks prior to registration.
  • Patients must not be on nonsteroidal antiandrogen blockade.
  • Patients must have no evidence of disease on bone scan or computed tomography (CT) scan of the abdomen/pelvis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PTK787

PTK787:

250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily
Drug: PTK787

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Time To Progression (TTP) in Weeks
Time Frame: 12 Months
12 Months

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of Toxicities in Patients Treated with PTK787
Time Frame: 30 Days After Last Dose
30 Days After Last Dose
Overall Survival
Time Frame: 12 Months
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

Novartis

Investigators

  • Principal Investigator: Kathleen W. Beekman, MD, The University of Michigan Comprehensive Cancer Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2005

Primary Completion (Actual)

November 1, 2006

Study Completion (Actual)

March 1, 2007

Study Registration Dates

First Submitted

August 23, 2005

First Submitted That Met QC Criteria

August 23, 2005

First Posted (Estimate)

August 24, 2005

Study Record Updates

Last Update Posted (Estimate)

January 19, 2015

Last Update Submitted That Met QC Criteria

January 15, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UMCC 2005.014

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe